Skip navigation
cbd_2.png

Outgoing FDA chief says new CBD laws are preferred to regulations

A nuanced regulatory rule would be too little, too late

Retiring Food and Drug Administration commissioner Scott Gottlieb, MD, said on Tuesday that a rule-making process by the FDA to deal with the booming—and controversial—CBD market would take more than three years to complete, and the most efficient way to deal with marijuana’s non-intoxicating cousin would be through legislation that would focus on CBD only.

Register to view the full article

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish